Samuel L Rice, Fernando Gómez Muñoz, Jamaal Benjamin, Seung Kim, Auh Whan Park, Joseph R Osborne, Regina Beets-Tan
{"title":"小分子和大分子治疗示踪剂探针在假血管分离后的原位OncoPIG肝肿瘤模型中的动脉内给药","authors":"Samuel L Rice, Fernando Gómez Muñoz, Jamaal Benjamin, Seung Kim, Auh Whan Park, Joseph R Osborne, Regina Beets-Tan","doi":"10.1007/s13139-024-00892-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Directed therapies employing small (SM) and large (LM) molecule drugs to target tumor antigens are used for treatment. Theranostics radiolabels them for imaging and radiation treatment. Poor radiopharmaceutical kinetics, prolonged circulating times, and high nontarget radiation to normal tissues after intravenous (i.v) injection limits translation. Intra-arterial (i.a.) procedures locally concentrate nonspecific chemotherapies or radiation to treat hepatic tumors (HT). Pseudovascular isolation (PVI), embolizes the HT arterioles, blocking efferent flow into capillaries isolating the HT from the systemic vasculature maximizing uptake to provide curative tumor specific absorbed radiation.</p><p><strong>Methods: </strong>[¹⁸F]Fluorodeoxyglucose (FDG) SM and <sup>99m</sup>Tc-labeled macroaggregated albumin (MAA) LM surrogates were used to assess biodistribution in a porcine HT. Injected dose per gram (%ID/g) of the tracers obtained from 1 to 120 min after control (i.v) and experimental i.a. infusion with PVI.</p><p><strong>Results: </strong>SM drug delivered to HT was 290-366% greater for PVI vs. i.v (60 min %ID/g 31.26 ± 2.55 vs. 8.83 ± 0.55, <i>p</i> = 0.033; 120 min 29.28 ± 1.44 vs. 8.94 ± 0.96, <i>p</i> = 0.145). Mean HT uptake of LM with PVI was up to 760% greater than i.v. without washout (60 min %ID/g 80.01 ± 2.87 vs. 10.61 ± 0.96 <i>p</i> = 0.001; 81.72 ± 3.0 vs. 11.98 ± 0.3 <i>p</i> = 0.001 at 120 min).</p><p><strong>Conclusion: </strong>PVI significantly increases the concentration of both SM and LM drugs within a HT compared to i.v. infusion. PVI with tumor specific drugs offers an opportunity to locally cure HT using a drug that specifically targets tumor antigens.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 4","pages":"217-228"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267727/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intra-Arterial Drug Delivery of Both a Small and Large Molecule Theranostic Radiotracer Probe into an Orthotopic OncoPIG Liver Tumor Model After Pseudovascular Isolation.\",\"authors\":\"Samuel L Rice, Fernando Gómez Muñoz, Jamaal Benjamin, Seung Kim, Auh Whan Park, Joseph R Osborne, Regina Beets-Tan\",\"doi\":\"10.1007/s13139-024-00892-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Directed therapies employing small (SM) and large (LM) molecule drugs to target tumor antigens are used for treatment. Theranostics radiolabels them for imaging and radiation treatment. Poor radiopharmaceutical kinetics, prolonged circulating times, and high nontarget radiation to normal tissues after intravenous (i.v) injection limits translation. Intra-arterial (i.a.) procedures locally concentrate nonspecific chemotherapies or radiation to treat hepatic tumors (HT). Pseudovascular isolation (PVI), embolizes the HT arterioles, blocking efferent flow into capillaries isolating the HT from the systemic vasculature maximizing uptake to provide curative tumor specific absorbed radiation.</p><p><strong>Methods: </strong>[¹⁸F]Fluorodeoxyglucose (FDG) SM and <sup>99m</sup>Tc-labeled macroaggregated albumin (MAA) LM surrogates were used to assess biodistribution in a porcine HT. Injected dose per gram (%ID/g) of the tracers obtained from 1 to 120 min after control (i.v) and experimental i.a. infusion with PVI.</p><p><strong>Results: </strong>SM drug delivered to HT was 290-366% greater for PVI vs. i.v (60 min %ID/g 31.26 ± 2.55 vs. 8.83 ± 0.55, <i>p</i> = 0.033; 120 min 29.28 ± 1.44 vs. 8.94 ± 0.96, <i>p</i> = 0.145). Mean HT uptake of LM with PVI was up to 760% greater than i.v. without washout (60 min %ID/g 80.01 ± 2.87 vs. 10.61 ± 0.96 <i>p</i> = 0.001; 81.72 ± 3.0 vs. 11.98 ± 0.3 <i>p</i> = 0.001 at 120 min).</p><p><strong>Conclusion: </strong>PVI significantly increases the concentration of both SM and LM drugs within a HT compared to i.v. infusion. PVI with tumor specific drugs offers an opportunity to locally cure HT using a drug that specifically targets tumor antigens.</p>\",\"PeriodicalId\":19384,\"journal\":{\"name\":\"Nuclear Medicine and Molecular Imaging\",\"volume\":\"59 4\",\"pages\":\"217-228\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267727/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13139-024-00892-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-024-00892-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
目的:采用小分子(SM)和大分子(LM)药物靶向肿瘤抗原进行定向治疗。放射治疗学将它们标记为成像和放射治疗。放射性药物动力学差,循环时间延长,静脉注射后对正常组织的高非靶辐射限制了转化。动脉内(i.a)手术局部集中非特异性化疗或放射治疗肝肿瘤(HT)。假血管隔离(PVI),栓塞HT小动脉,阻断进入毛细血管的输出流,将HT从全身血管中分离出来,最大限度地吸收,提供治疗性肿瘤特异性吸收辐射。方法:[¹⁸F]采用氟脱氧葡萄糖(FDG) SM和99mtc标记的大聚集白蛋白(MAA) LM替代品来评估猪HT中的生物分布。在对照(静脉注射)和实验性静脉注射PVI后1 ~ 120分钟内示踪剂的每克注射剂量(%ID/g)。结果:PVI组给药剂量比iv组高290 ~ 366% (60 min %ID/g 31.26±2.55比8.83±0.55,p = 0.033;120分钟29.28±1.44和8.94±0.96,p = 0.145)。PVI组LM的平均HT摄取量比未冲洗组ig高760% (60 min %ID/g 80.01±2.87 vs. 10.61±0.96 p = 0.001;81.72±3.0和11.98±0.3在120分钟p = 0.001)。结论:与静脉滴注相比,PVI显著增加了HT内SM和LM药物的浓度。PVI结合肿瘤特异性药物提供了使用特异性靶向肿瘤抗原的药物局部治愈HT的机会。
Intra-Arterial Drug Delivery of Both a Small and Large Molecule Theranostic Radiotracer Probe into an Orthotopic OncoPIG Liver Tumor Model After Pseudovascular Isolation.
Purpose: Directed therapies employing small (SM) and large (LM) molecule drugs to target tumor antigens are used for treatment. Theranostics radiolabels them for imaging and radiation treatment. Poor radiopharmaceutical kinetics, prolonged circulating times, and high nontarget radiation to normal tissues after intravenous (i.v) injection limits translation. Intra-arterial (i.a.) procedures locally concentrate nonspecific chemotherapies or radiation to treat hepatic tumors (HT). Pseudovascular isolation (PVI), embolizes the HT arterioles, blocking efferent flow into capillaries isolating the HT from the systemic vasculature maximizing uptake to provide curative tumor specific absorbed radiation.
Methods: [¹⁸F]Fluorodeoxyglucose (FDG) SM and 99mTc-labeled macroaggregated albumin (MAA) LM surrogates were used to assess biodistribution in a porcine HT. Injected dose per gram (%ID/g) of the tracers obtained from 1 to 120 min after control (i.v) and experimental i.a. infusion with PVI.
Results: SM drug delivered to HT was 290-366% greater for PVI vs. i.v (60 min %ID/g 31.26 ± 2.55 vs. 8.83 ± 0.55, p = 0.033; 120 min 29.28 ± 1.44 vs. 8.94 ± 0.96, p = 0.145). Mean HT uptake of LM with PVI was up to 760% greater than i.v. without washout (60 min %ID/g 80.01 ± 2.87 vs. 10.61 ± 0.96 p = 0.001; 81.72 ± 3.0 vs. 11.98 ± 0.3 p = 0.001 at 120 min).
Conclusion: PVI significantly increases the concentration of both SM and LM drugs within a HT compared to i.v. infusion. PVI with tumor specific drugs offers an opportunity to locally cure HT using a drug that specifically targets tumor antigens.
期刊介绍:
Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor.
The Korean Society of Nuclear Medicine (KSNM)
KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.